Unlock stock picks and a broker-level newsfeed that powers Wall Street. Upgrade Now
IOB - Delayed Quote USD

Pfizer Inc. (0Q1N.IL)

Compare
25.95
-0.20
(-0.76%)
At close: February 28 at 7:11:58 PM GMT

Key Executives

Amounts are as of December 31, 2022 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
NameTitlePayExercisedYear Born
Dr. Albert Bourla D.V.M., Ph.D. Chairman & CEO 11.72M -- 1962
Mr. Frank A. D'Amelio CFO & Exec. VP -- -- 1958
Mr. David M. Denton Chief Financial Officer & Exec. VP 18.19M -- 1965
Dr. Mikael Dolsten M.D., Ph.D. Chief Scientific Officer and Pres of R&D 5.82M -- 1958
Ms. Angela Hwang Chief Commercial Officer & Pres of Global Biopharmaceuticals Bus. 4.89M 7.7M 1966
Ms. Jennifer B. Damico Sr. VP, Controller & Principal Accounting Officer -- -- 1968
Ms. Lidia L. Fonseca Exec. VP and Chief Digital & Technology Officer -- -- 1969
Ms. Francesca M. DeMartino Chief Investor Relations Officer -- -- --
Mr. Douglas M. Lankler Exec. VP & Gen. Counsel -- -- 1966
Mr. Rady A. Johnson Exec. VP and Chief Compliance, Quality & Risk Officer -- -- 1962

Pfizer Inc.

66 Hudson Boulevard East
New York, NY 10001-2192
United States
212 733 2323 https://www.pfizer.com
Sector: 
Healthcare
Full Time Employees: 
83,000

Description

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Retacrit, Lorbrena, and Braftovi brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc., as well as strategic partnership with CSPC Pharmaceutical Group Limited to launch a local brand of the COVID-19 oral therapeutic treatment Nirmatrelvir/Ritonavir in China, and a collaboration with Carrick Therapeutics Limited. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Corporate Governance

Pfizer Inc.’s ISS Governance QualityScore as of October 1, 2023 is 5. The pillar scores are Audit: 10; Board: 5; Shareholder Rights: 1; Compensation: 3.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Upcoming Events

April 29, 2025 at 12:30 PM UTC - May 5, 2025 at 12:30 PM UTC

Pfizer Inc. Earnings Date

Recent Events

November 8, 2023 at 12:00 AM UTC

Ex-Dividend Date

Related Tickers